This review paper addresses the clinical and practical challenges posed by the COVID-19 pandemic and its effects on drug treatment.
A key focus is the heightened vulnerability of individuals with substance use disorders, a condition that has become even more precarious in light of the ongoing pandemic and the increased risk of acute respiratory infections.
The paper offers general guidance for treating substance use disorders, providing valuable insights for both treatment providers and managers of treatment systems.
Ultimately, the goal is to enhance patient services and mitigate virus transmission for both patients and providers.